Kenvue's stock tumbled when U.S. President Donald Trump, with Health & Human Services Secretary Robert F. Kennedy, Jr., standing behind him, declared that its product, Tylenol, leads to autism in children when taken by mothers during pregnancy. As social channels were flooded with misinformation supporting the evidenceless claim, it's easy to imagine the stock continuing to slide, mirroring the trajectory launched by attacks on Bud Light.

Remarkably, the stock recovered after one day, thanks largely to Tylenol's savvy and almost perfect response to the crisis.

Tylenol isn't the first brand to find itself in President Trump's crosshairs. It is unlikely to be the last. In this short, midweek episode, Neville and Shel explore what the company got right, and what other companies can do to prepare for their turn in the glare of the presidential spotlight.
Continue Reading →

The post FIR #483: How Tylenol Handled a High-Profile Falsehood appeared first on FIR Podcast Network.